Resistance to Glycopeptides

Staphylococci in Human Disease: Second Edition

Volumn , Issue , 2009, Pages 193-209

  Hiramatsu, Keiichi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Altered susceptibilities of VISA strains to other antibiotics; Clinical significance of hetero VISA; Clonal expansion of homo MRSA of clonotype II A in Japanese hospitals; Genes of interest associated with vancomycin resistance; Glycopeptide resistance; Hetero VISA detection; Vancomycin resistance in Japan; Vancomycin intermediate S. aureus (VISA); VISA and hetero VISA; VISA and VRSA emergence

Indexed keywords

EID: 84865601095     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444308464.ch9     Document Type: Chapter

References (78)

1. Jevons M. Celbenin-resistant staphylococci. BMJ 1961;1:124-5.
2. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6.
3. Hiramatsu K. Vancomycin resistance in staphylococci. Drug Resist Updat 1998;1:135-50.
4. Watanakunakorn C. Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother 1984;14(suppl D):7-18.
5. Higgins DL, Chang R, Debabov DV et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:1127-34.
6. Arthur M, Reynolds PE, Depardieu F et al. Mechanisms of glycopeptide resistance in enterococci. J Infect 1996;32:11-16.
7. Ito T, Katayama Y, Hiramatsu K. Cloning and nucleotide sequence determination of the entire mec DNA of pre-methicillinresistant Staphylococcus aureus N315. Antimicrob Agents Chemother 1999;43:1449-58.
8. Kuroda M, Ohta T, Uchiyama I et al. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 2001; 357:1225-40.
9. Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2000;44:1549-55.
10. Ito T, Okuma K, Ma XX, Yuzawa H, Hiramatsu K. Insights on antibiotic resistance of Staphylococcus aureus from its whole genome: genomic island SCC. Drug Resist Updat 2003;6:41-52.
11. Centers for Disease Control. Vancomycin-resistant Staphylococcus aureus: Pennsylvania, 2002. MMWR 2002;51:902.
12. Centers for Disease Control. Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR 2002;51:565-7.
13. Arthur M, Depardieu F, Reynolds P, Courvalin P. Quantitative analysis of the metabolism of soluble cytoplasmic peptidoglycan precursors of glycopeptide-resistant enterococci. Mol Microbiol 1996;21:33-44.
14. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72:195-8.
15. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 15th Informational Supplement M100-S15. Wayne, PA: Clinical and Laboratory Standards Institute, 2005.
16. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med 1998;104:7S-10S.
17. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987;316:927-31.
18. Sanyal D, Johnson AP, George RC, Cookson BD, Williams AJ. Peritonitis due to vancomycin-resistant Staphylococcus epidermidis. Lancet 1991;337:54.
19. Wilson AP, O'Hare MD, Felmingham D, Gruneberg RN. Teicoplanin-resistant coagulase-negative staphylococcus. Lancet 1986;ii:973.
20. Takeuchi F, Watanabe S, Baba T et al. Whole-genome sequencing of Staphylococcus haemolyticus uncovers the extreme plasticity of its genome and the evolution of human-colonizing staphylococcal species. J Bacteriol 2005;187:7292-308.
21. Watanabe S, Ito T, Morimoto Y, Takeuchi F, Hiramatsu K. Precise excision and self-integration of a composite transposon as a model for spontaneous large-scale chromosome inversion/ deletion of the Staphylococcus haemolyticus clinical strain JCSC1435. J Bacteriol 2007;189:2921-5.
22. Hiramatsu K, Kapi M, Tajima Y, Cui L, Trakulsomboon S, Ito T. Advances in vancomycin resistance: research in Staphylococcus aureus. In: White DG, Alekshun MN, McDermott PF, eds. Frontiers in Antimicrobial Resistance: a Tribute to Stuart B. Levy. Washington, DC: ASM Press, 2005:289-98.
23. Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol 2002;56:657-75.
24. Hiramatsu K, Aritaka N, Hanaki H et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670-3.
25. Fridkin SK, Hageman J, McDougal LK et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003;36:429-39.
26. Hiramatsu K, Cui L, Kuroda M, Ito T. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol 2001;9:486-93.
27. Hiramatsu K, Kondo N, Ito T. Genetic basis for molecular epidemiology of MRSA. J Infect Chemother 1996;2:117-29.
28. Oliveira DC, Tomasz A, de Lencastre H. The evolution of pandemic clones of methicillin-resistant Staphylococcus aureus: identification of two ancestral genetic backgrounds and the associated mec elements. Microb Drug Resist 2001;7:349-61.
29. Song JH, Hiramatsu K, Suh JY et al. Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2004;48:4926-8.
30. Chongtrakool P, Ito T, Ma XX et al. Staphylococcal cassette chromosome mec (SCCmec) typing of methicillin-resistant Staphylococcus aureus strains isolated in 11 Asian countries: a proposal for a new nomenclature for SCCmec elements. Antimicrob Agents Chemother 2006;50:1001-12.
31. Hiramatsu K, Cui L, Kuwahara-Arai K. Has vancomycinresistant Staphylococcus aureus started going it alone? Lancet 2004;364:565-6.
32. Tanaka T, Okuzumi K, Iwamoto A, Hiramatsu K. A retrospective study on methicillin-resistant Staphylococcus aureus clinical strains in Tokyo University Hospital. J Infect Chemother 1995; 1:42-51.
33. Hiramatsu K. Molecular evolution of MRSA. Microbiol Immunol 1995;39:531-43.
34. Sabath LD, Wallace SJ. Factors influencing methicillin resistance in staphylococci. Ann NY Acad Sci 1971;182:258-66.
35. Matthews PR, Stewart PR. Resistance heterogeneity in methicillin-resistant Staphylococcus aureus. FEMS Microbiol Lett 1984;22:161-6.
36. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001;1:147-55.
37. Cui L, Ma X, Sato K et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2003;41:5-14.
38. Haraga I, Nomura S, Fukamachi S et al. Emergence of vancomycin resistance during therapy against methicillin-resistant Staphylococcus aureus in a burn patient: importance of low-level resistance to vancomycin. Int J Infect Dis 2002;6:302-8.
39. Hanaki H, Nomura S, Akagi H, Hiramatsu K. Improvement of water-soluble cephalosporin derivatives having antibacterial activity against methicillin-resistant Staphylococcus aureus. Chemotherapy 2001;47:170-6.
40. Trakulsomboon S, Danchaivijitr S, Rongrungruang Y et al. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. J Clin Microbiol 2001;39:591-5.
41. Aritaka N, Hanaki H, Cui L, Hiramatsu K. Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin. Antimicrob Agents Chemother 2001;45:1292-4.
42. Voss A, Mouton JW, Elzakker EP et al. A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA). Ann Clin Microbiol Antimicrob 2007;6:9.
43. Hiramatsu K, Watanabe S, Takeuchi F, Ito T, Baba T. Genetic characterization of methicillin-resistant Staphylococcus aureus. Vaccine 2004;22(suppl 1):S5-S8.
44. Marlowe EM, Cohen MD, Hindler JF, Ward KW, Bruckner DA. Practical strategies for detecting and confirming vancomycinintermediate Staphylococcus aureus: a tertiary-care hospital laboratory's experience. J Clin Microbiol 2001;39:2637-9.
45. Kuroda M, Kuwahara-Arai K, Hiramatsu K. Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method. Biochem Biophys Res Commun 2000;269:485-90.
46. Severin A, Tabei K, Tenover F, Chung M, Clarke N, Tomasz A. High level oxacillin and vancomycin resistance and altered cell wall composition in Staphylococcus aureus carrying the staphylococcal mecA and the enterococcal vanA gene complex. J Biol Chem 2004;279:3398-407.
47. Weigel LM, Clewell DB, Gill SR et al. Genetic analysis of a highlevel vancomycin-resistant isolate of Staphylococcus aureus. Science 2003;302:1569-71.
48. Pinho MG, Filipe SR, de Lencastre H, Tomasz A. Complementation of the essential peptidoglycan transpeptidase function of penicillin-binding protein 2 (PBP2) by the drug resistance protein PBP2A in Staphylococcus aureus. J Bacteriol 2001;183: 6525-31.
49. Fox PM, Lampen RJ, Stumpf KS, Archer GL, Climo MW. Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and beta-lactam antibiotics. Antimicrob Agents Chemother 2006;50:2951-6.
50. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu K. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 1998;42:199-209.
51. Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H, Hiramatsu K. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J Antimicrob Chemother 1998;42:315-20.
52. Stranden AM, Roos M, Berger-Bachi B. Glutamine synthetase and heteroresistance in methicillin-resistant Staphylococcus aureus. Microb Drug Resist 1996;2:201-7.
53. Cui L, Iwamoto A, Lian JQ et al. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:428-38.
54. Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K. Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol Microbiol 2003;49:807-21.
55. Gardete S, Wu SW, Gill S, Tomasz A. Role of VraSR in antibiotic resistance and antibiotic-induced stress response in Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:3424-34.
56. Neoh H-M, Cui L, Yuzawa H, Takeuchi F, Hiramatsu K. Mutated response-regulator graR is responsible for hetero-VISA to VISA phenotypic conversion of vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2007;52:45-53.
57. Cui L, Lian JQ, Neoh HM, Reyes E, Hiramatsu K. DNA microarray- based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:3404-13.
58. Ruzin A, Severin A, Moghazeh SL et al. Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureus. Biochim Biophys Acta 2003;1621:117-21.
59. Staubitz P, Neumann H, Schneider T, Wiedemann I, Peschel A. MprF-mediated biosynthesis of lysylphosphatidylglycerol, an important determinant in staphylococcal defensin resistance. FEMS Microbiol Lett 2004;231:67-71.
60. Hiramatsu K, Hanaki H. Glycopeptide resistance in staphylococci. Curr Opin Infect Dis 1998;11:653-8.
61. Sieradzki K, Pinho MG, Tomasz A. Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus. J Biol Chem 1999;274:18942-6.
62. Morikawa K, Maruyama A, Inose Y, Higashide M, Hayashi H, Ohta T. Overexpression of sigma factor, sigma(B), urges Staphylococcus aureus to thicken the cell wall and to resist betalactams. Biochem Biophys Res Commun 2001;288:385-9.
63. Peschel A, Vuong C, Otto M, Götz F. The d-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes. Antimicrob Agents Chemother 2000;44:2845-7.
64. Nishi H, Komatsuzawa H, Fujiwara T, McCallum N, Sugai M. Reduced content of lysyl-phosphatidylglycerol in the cytoplasmic membrane affects susceptibility to moenomycin, as well as vancomycin, gentamicin, and antimicrobial peptides, in Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48:4800-7.
65. Brandenberger M, Tschierske M, Giachino P, Wada A, Berger- Bachi B. Inactivation of a novel three-cistronic operon tcaR-tcaAtcaB increases teicoplanin resistance in Staphylococcus aureus. Biochim Biophys Acta 2000;1523:135-9.
66. Maki H, McCallum N, Bischoff M, Wada A, Berger-Bachi B. tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2004;48:1953-9.
67. Kaatz GW, Thyagarajan RV, Seo SM. Effect of promoter region mutations and mgrA overexpression on transcription of norA, which encodes a Staphylococcus aureus multidrug efflux transporter. Antimicrob Agents Chemother 2005;49:161-9.
68. Singh VK, Moskovitz J. Multiple methionine sulfoxide reductase genes in Staphylococcus aureus: expression of activity and roles in tolerance of oxidative stress. Microbiology 2003;149:2739- 47.
69. Rossi J, Bischoff M, Wada A, Berger-Bachi B. MsrR, a putative cell envelope-associated element involved in Staphylococcus aureus sarA attenuation. Antimicrob Agents Chemother 2003; 47:2558-64.
70. Sakoulas G, Eliopoulos GM, Fowler VG Jr et al. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother 2005;49:2687-92.
71. Sakoulas G, Eliopoulos GM, Moellering RC Jr et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002;46:1492-502.
72. Shlaes DM, Shlaes JH. Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin. Clin Infect Dis 1995;20:1071- 3.
73. Kaatz GW, Seo SM, Dorman NJ, Lerner SA. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis 1990;162:103-8.
74. Shlaes DM, Shlaes JH, Vincent S, Etter L, Fey PD, Goering RV. Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillinbinding protein 2 complex. Antimicrob Agents Chemother 1993;37:2432-7.
75. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:1079-82.
76. Tajima Y, Komatsu M, Ito T, Hiramatsu K. Rapid detection of Staphylococcus aureus strains having reduced susceptibility to vancomycin using a chemiluminescence-based drug-susceptibility test. J Microbiol Methods 2007;70:434-41.
77. Leclercq R, Derlot E, Weber M, Duval J, Courvalin P. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1989;33:10-15.
78. Cui L, Neoh HM, Shoji M, Hiramatsu K. Contribution of vraSR and graSR Point Mutations to Vancomycin Resistance in Vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2009 Mar; 53(3):1231-4.